Every Form 4 that Nuvation Bio Inc (NUVB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NUVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUVB filings page.
Nuvation Bio Inc. (NUVB) reported that Chief Scientific Officer Gary Hattersley exercised options for 100,000 shares of Class A Common Stock at an exercise price of $1.87 per share and sold 100,000 shares on the same date at a weighted-average price of $7.0924, under a Rule 10b5-1 trading plan dated December 4, 2025. Following the option exercise, he held 400,000 stock options directly, with the option expiring on February 27, 2034 and vesting 25% after one year from February 29, 2024 and monthly over the next 36 months, subject to continued service.
Nuvation Bio Inc. reports that Chief Financial Officer Philippe Sauvage exercised employee stock options covering 40,000 shares of Class A common stock on July 15, 2026 through two transactions at exercise prices of $1.97 and $2.17 per share. Corresponding option positions were reduced, while the acquired shares are held directly. Footnotes state that the reported common share balance includes 1,458 shares purchased through the employee stock purchase plan on May 19, 2026, and describe option grants that vest 25% on the one-year anniversaries of October 7, 2024 and February 28, 2025 and monthly over the following 36 months, subject to continued service.
Nuvation Bio Inc. chief people officer Stacy Markel exercised stock options and sold shares in the company. On June 23, 2026, Markel exercised options for 34,620 shares at $1.74 per share and 90,380 shares at $1.87 per share, then sold 125,000 Class A common shares in an open-market transaction at a weighted-average price of $6.0255 per share, with trades ranging from $6.00 to $6.085, under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Markel directly holds 32,591 Class A common shares.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options and sold shares in the company. Wentworth exercised options to acquire 63,000 shares of Class A common stock at an exercise price of $2.93 per share, then sold 63,000 shares in an open-market transaction at a weighted-average price of $6.0189 per share. The sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. Following these transactions, Wentworth directly holds 53,000 shares of Class A common stock.
Nuvation Bio Inc. Chief Financial Officer Philippe Sauvage exercised stock options and sold shares in a coordinated transaction. He exercised options to acquire 47,668 shares of Class A common stock at $2.17 per share, then sold 47,668 shares in open-market trades at a weighted-average price of $6.0076 per share under a Rule 10b5-1 trading plan dated December 4, 2025. Following these transactions, he directly holds 12,673 shares of Class A common stock.
Nuvation Bio Inc. director Robert Mashal, through the Robert D. Mashal 2020 Revocable Trust for which he is sole trustee, made an open-market purchase of 25,000 shares of Class A Common Stock at $4.73 per share. After this indirect transaction by the trust, total holdings reported for this trust-related position increased to 225,000 shares of Nuvation Bio Class A Common Stock.
Nuvation Bio Inc. director Vernon W. Anthony received a grant of stock options covering 123,397 shares of Class A common stock. The options have an exercise price of $4.79 per share and expire on May 20, 2036. All 123,397 shares subject to the option will vest on the earlier of May 21, 2026 or the next shareholder annual meeting, provided he remains in continuous service through that date. Following this compensation-related award, he holds 123,397 options directly, and the filing does not report any open-market buying or selling.
Nuvation Bio Inc. director Robert Mashal received a grant of stock options covering 123,397 shares of Class A common stock at an exercise price of $4.79 per share. These options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, contingent on his continuous service. Following the grant, he holds options for 123,397 shares directly, expiring on May 20, 2036.
Nuvation Bio Inc. director Kathryn E. Falberg received a grant of stock options covering 123,397 shares of Class A common stock at an exercise price of $4.79 per share. The options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, subject to her continuous service, and expire on May 20, 2036. Following this award, she holds 123,397 derivative securities directly.
Nuvation Bio Inc. reported that director Kim D. Blickenstaff received a grant of stock options. The award covers 123,397 options to buy Class A common stock at an exercise price of $4.79 per share, expiring on May 20, 2036.
All of the options vest 100% on the earlier of May 21, 2026 or the next shareholder annual meeting, as long as the director remains in continuous service. Following this grant, the filing shows 123,397 derivative securities held directly, with no open‑market purchases or sales reported.
Nuvation Bio Inc. director Robert B. Bazemore received a stock option grant covering 123,397 shares of Class A common stock. The option has an exercise price of $4.79 per share and expires on May 20, 2036. All shares vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, subject to his continuous service. This is a compensation-related award, with no open-market share purchases or sales reported.
Nuvation Bio Inc. director Xiangmin Cui reported receiving a stock option grant on Class A common stock. The award covers 123,397 options with an exercise price of $4.79 per share and expires on May 20, 2036. Following this grant, Cui holds 123,397 derivative securities linked to the company’s Class A common stock.
According to the terms, 100% of the options will vest on the earlier of May 21, 2026 or the next shareholder annual meeting, provided Cui remains in continuous service through that vesting date. This filing reflects a compensation-related acquisition rather than an open-market purchase or sale.
Nuvation Bio Inc. director Xiangmin Cui corrected a prior insider report to show a grant of 76,923 stock options for Class A common stock received on February 27, 2026. These options have a $5.91 exercise price, expire on February 26, 2036, and vest in 24 monthly installments starting from January 1, 2026.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised options and sold shares in a planned transaction. On April 17, 2026, Wentworth exercised options to acquire 36,750 shares of Class A common stock at $2.93 per share, then sold 36,750 shares in open-market trades at a weighted-average price of $5.0144 under a Rule 10b5-1 trading plan. After these transactions, Wentworth directly owns 53,000 shares of Nuvation Bio Class A common stock.
Nuvation Bio Inc. chief medical officer Dongfang Liu reported an exercise-and-sell transaction in Class A common stock. Liu exercised stock options to acquire 50,000 shares at $1.94 per share, then sold 50,000 shares in open-market trades at a weighted-average price of $5.02 per share.
The sales, executed at prices ranging from $5.00 to $5.07, were made under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Liu holds 18,000 shares of Class A common stock and 430,000 stock options expiring on February 27, 2033.
Nuvation Bio Inc. chief regulatory officer Kerry Wentworth exercised stock options for a total of 200,000 shares of Class A Common Stock on April 6, 2026, at exercise prices of $1.87 and $1.94 per share. The same day, Wentworth sold 200,000 shares in open-market transactions at a weighted-average price of $4.5178 per share, with individual sale prices ranging from $4.44 to $4.64, pursuant to a pre-arranged Rule 10b5-1 trading plan. After these transactions, Wentworth directly holds 53,000 shares of Class A Common Stock.
Nuvation Bio Inc. reported that its Chief Medical Officer, Dongfang Liu, received a grant of stock options covering 748,130 shares of common stock. The award is classified as a grant or other acquisition rather than an open-market purchase.
According to the terms, the option vests as to 25% of the underlying shares on the one-year anniversary of February 27, 2026, with the remaining portion vesting in equal monthly installments over the following 36 months. Vesting is conditioned on Dr. Liu’s continuous service with the company on each applicable vesting date.
Nuvation Bio Inc. reported that officer Makunje Moses received new equity awards. On February 27, 2026, Moses was granted stock options for 224,439 shares at an exercise price of $0.00 per share and 50,761 shares of Class A Common Stock as restricted stock units (RSUs).
The stock option vests 25% on the one-year anniversary of February 27, 2026, then monthly over the next 36 months, contingent on continued service. The RSUs vest in four equal annual installments on the issuer’s quarterly vesting date following each of the first four anniversaries from February 27, 2026, also conditioned on continued service.
Nuvation Bio Inc. reported that Chief Regulatory Officer Kerry Wentworth received a grant of stock options covering 748,130 shares of common stock on February 27, 2026. The option has an exercise price of $0.00 per share and vests 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to continued service. Following this grant, Wentworth also holds 53,000 shares of Class A common stock, including 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc.'s Chief Commercial Officer, Colleen Sjogren, received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest as to 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to her continuous service. Following this grant, she directly owned 84,000 shares of Class A common stock, which includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc. reported that Chief Financial Officer Philippe Sauvage received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to his continuous service.
Following this grant, Sauvage directly holds 12,673 shares of Class A common stock. This total includes 2,771 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc. reported that its Chief People Officer, Markel Stacy, was granted a stock option covering 748,130 shares of Class A common stock on February 27, 2026. The option vests 25% on the one-year anniversary of February 27, 2026 and then monthly over the following 36 months, contingent on her continued service.
After this grant, Stacy holds 748,130 stock options and 32,591 shares of Class A common stock directly, including 3,000 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.
Cui Xiangmin reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that director Xiangmin Cui received a grant of stock options covering 74,813 shares on February 27, 2026. The options have a grant price of $0.00 per share and represent a right to buy company stock rather than immediate ownership.
According to the terms, the option vests as to 1/24 of the shares on the one-month anniversary of January 1, 2026, and then monthly over the following 23 months, as long as Cui remains in continuous service on each vesting date. After this grant, Cui holds 74,813 stock options directly.
Hattersley Gary reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that its Chief Scientific Officer, Gary Hattersley, received a grant of stock options covering 748,130 shares of common stock. The options were awarded at a grant price of $0.00 per option, reflecting a non-cash compensation award rather than an open-market purchase.
According to the vesting terms, 25% of the option grant will vest on the one-year anniversary of 2/27/2026, with the remaining portion vesting in equal monthly installments over the following 36 months, subject to his continuous service on each vesting date.
Nuvation Bio Inc. reported that its Chief Technical Operations officer, David C. Hanley, received a grant of 748,130 stock options. These options were acquired as a derivative security award and increase his directly held option position to 748,130 options.
According to the terms, the option vests as to 25% on the one-year anniversary of February 27, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on Hanley’s continuous service on each vesting date.
Hung David reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that President and CEO David Hung received a grant of stock options covering 1,995,012 shares. These options were awarded at no cash cost to him as a grant, not an open-market purchase.
According to the disclosure, the option vests 25% on the one-year anniversary of 2/27/2026, with the remaining shares vesting monthly over the following 36 months, as long as he continues in service on each vesting date.
Nuvation Bio Inc. reported insider equity transactions by its Chief Medical Officer. On 12/01/2025, the officer exercised stock options to acquire 150,000 shares of Class A common stock at an exercise price of $2.93 per share. On the same date, the officer sold 150,000 shares of Class A common stock in an open-market transaction with a weighted-average sales price of $7.8217 per share, with individual sale prices ranging from $7.80 to $7.855.
After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 165,000 stock options that remain outstanding, each option relating to Class A common stock. The option originally covered 150,000 shares, vested 25% after one year from 08/29/2022 and monthly over the following 36 months, conditioned on continued service.
Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer. On 11/25/2025, the officer exercised 10,000 stock options for Class A common stock at $3.61 per share and sold 10,000 shares at $7.50 per share, leaving 18,000 shares directly owned. On 11/26/2025, the officer again exercised 10,000 options at $3.61 and sold 10,000 shares at $8.00, with direct ownership again reported as 18,000 shares. These trades came from stock options with a $3.61 exercise price and an expiration date of 07/14/2032. After the reported option exercises, the officer still holds 470,000 stock options, which continue to vest monthly following an initial 25% vest on the one-year anniversary of 07/15/2022.
Nuvation Bio Inc. (NUVB) Chief Scientific Officer reported option exercises and same-day share sales. On 11/20/2025, the insider exercised 69,051 stock options at $1.74 per share and 300,000 stock options at $1.94 per share, receiving the same number of Class A common shares.
That same day, the insider sold 69,051 and 300,000 Class A common shares at a weighted-average price of $7.227 per share in separate transactions, leaving 0 shares of common stock directly owned afterward. Following these transactions, the insider continued to hold 229,884 options with a $1.74 exercise price expiring on 01/21/2030 and 200,000 options with a $1.94 exercise price expiring on 02/27/2033.
Nuvation Bio Inc. (NUVB) reported an insider equity transaction by its Chief Medical Officer. On 11/20/2025, the officer exercised a stock option to buy 20,000 shares of Class A common stock at $1.87 per share and then sold 20,000 shares of Class A common stock in an open-market transaction at a weighted-average price of $7.0037 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 450,000 stock options with an exercise price of $1.87 per share, expiring on 02/27/2034. The option vests 25% on the one-year anniversary of 02/29/2024 and monthly over the following 36 months, subject to continuous service.
Nuvation Bio Inc. (NUVB) reported an insider transaction by its Chief Technical Operations officer. On 11/19/2025, the officer exercised 200,000 stock options at an exercise price of $1.87 per share, converting them into Class A common stock. On the same date, the officer sold 200,000 Class A common shares at a weighted-average price of $7.1384 per share. After these transactions, the officer directly held 24,000 shares of Class A common stock and 300,000 stock options. The filing notes additional shares acquired through the company’s 2021 Employee Stock Purchase Plan and describes the vesting schedule for the option grant.
Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer on Form 4. On 11/17/2025 and 11/19/2025, the officer exercised stock options to buy a total of 30,000 shares of Class A common stock at an exercise price of $1.87 per share and sold 30,000 shares in open-market transactions.
The sales included 15,000 shares on 11/17/2025 at $4.765 per share and 15,000 shares on 11/19/2025 at a weighted-average price of $5.1035 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock and held 470,000 stock options with a $1.87 exercise price expiring on 02/27/2034.
Nuvation Bio (NUVB) insider transaction: The Chief Scientific Officer executed a stock option exercise for 100,000 Class A shares at $1.74 (code M) on 10/27/2025 and sold 100,000 shares at a weighted-average price of $5.0246 (code S) pursuant to a Rule 10b5-1 plan dated June 24, 2024.
Following the transactions, non-derivative holdings were 0 shares. Derivative holdings included 298,935 stock options. The option grant referenced vests 25% on July 1, 2020, with the remainder in equal monthly installments over three years.